Tecentriq Takes EU Lead In Triple-Negative Breast Cancer

 
• By John Davis

Roche’s checkpoint inhibitor has been approved in combination with nab-paclitaxel in the EU for triple-negative breast cancer, cementing the company’s role as an innovator in breast cancer therapies.  

Cycling
Roche is ahead of the field in triple-negative breast cancer • Source: Shutterstock

More from Immuno-oncology

More from Anticancer